chevron_leftBack
As of 14 June 2026, Cyclerion Therapeutics, Inc. has a market cap of $14.03M USD, ranking #39373 globally and #5178 in the United States.
It ranks #3507 in the Healthcare sector, and #1147 in the Drug Manufacturers - General industry.
Key Stats
Market Cap
$14.03MUSD
Enterprise Value
$10.79MUSD
Revenue (TTM)
$2.07MUSD
Net Income (TTM)
-$3.53MUSD
Profit Margin
-170%
PS Ratio
6.8
PB Ratio
1.3
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Regina Graul
open_in_new
Employees
1
Founded
2018
Website
cyclerion.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| 9.2% | 11% | 121% | 129% | 63% | -10% |
News
Loading...
CYCN Analyst Forecasts
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
CYCN
Cyclerion Therapeutics Inc Ordinary Shares
ISIN: US23255M2044
Shares Out.:
Shares Outstanding:
4.33M1
Shares Float:
3.236M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
NQ:
NASDAQ:
BA:
Barron's:
MS:
Morningstar:
|
3.32 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Cyclerion Therapeutics, Inc.
Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases serious diseases with novel sGC stimulators in both the central nervous system (CNS) and the periphery. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to treat cardiovascular diseases; and Praliciguat, a systemic sGC stimulator for the treatment of rare kidney disease. It has a license agreement with Akebia to develop, manufacture, medical affair, and commercializes Praliciguat and other related products. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NYSE: LLY
|
$761.68B
5M%
|
38.1
|
|
NYSE: JNJ
|
$547.28B
4M%
|
26.4
|
|
NYSE: ABBV
|
$360.63B
3M%
|
97.4
|
|
NYSE: MRK
|
$274.03B
2M%
|
15.1
|
|
NYSE: PFE
|
$149.38B
1M%
|
19.5
|
|
NYSE: BMY
|
$117.58B
838K%
|
16.8
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
SIX: RO
|
$321.52B
2M%
256.25B CHF
|
19.9
|
|
LSE: AZN
|
$288.84B
2M%
215.59B GBP
|
27.6
|
|
SIX: NOVN
|
$274.65B
2M%
218.9B CHF
|
20.5
|
|
CPH: NOVO-B
|
$181.82B
1M%
1.18T DKK
|
11.5
|
|
EPA: SAN
|
$110.1B
785K%
95.26B EUR
|
19.9
|
|
LSE: GSK
|
$108.46B
773K%
80.96B GBP
|
14.6
|
chevron_leftBack